Acadia Healthcare (NASDAQ:ACHC) Releases Earnings Results, Beats Estimates By $0.14 EPS

Key Points

• Acadia Healthcare reported quarterly EPS of $0.60, beating consensus by $0.14, while revenue of $895.31 million also topped estimates and grew 5.1% year over year. EPS was down from $0.72 in the year-ago quarter.
• Shares rose 8.9% to $32.25 in midday trading after the results.
• Analysts’ consensus rating is Hold, with an average price target of $30.69; recent targets ranged from $33 to $39, alongside a mix of Buy, Hold, and Sell ratings.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.14, FiscalAI reports. Acadia Healthcare had a negative net margin of 33.44% and a positive return on equity of 6.19%. The company had revenue of $895.31 million for the quarter, compared to analyst estimates of $877.76 million. During the same period in the prior year, the firm posted $0.72 EPS. The company's quarterly revenue was up 5.1% on a year-over-year basis.

Acadia Healthcare Stock Up 8.9%

Acadia Healthcare stock traded up $2.63 during midday trading on Wednesday, reaching $32.25. The stock had a trading volume of 5,055,130 shares, compared to its average volume of 1,622,090. Acadia Healthcare has a 12 month low of $11.43 and a 12 month high of $35.83. The company has a market capitalization of $3.00 billion, a P/E ratio of -2.59, a PEG ratio of 9.54 and a beta of 0.64. The company has a fifty day moving average price of $29.18 and a two-hundred day moving average price of $25.91. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 1.20.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Raymond James Financial downgraded shares of Acadia Healthcare from a "strong-buy" rating to an "outperform" rating and set a $39.00 target price for the company. in a research note on Monday, September 28th. TD Cowen upped their price target on shares of Acadia Healthcare from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, July 14th. Leerink Partners increased their price target on Acadia Healthcare from $30.00 to $33.00 and gave the stock a "market perform" rating in a report on Wednesday, September 23rd. UBS Group lifted their price objective on Acadia Healthcare from $31.00 to $39.00 and gave the stock a "buy" rating in a research report on Thursday, July 9th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Acadia Healthcare in a research report on Tuesday, October 6th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Acadia Healthcare has an average rating of "Hold" and a consensus target price of $30.69.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services headquartered in Franklin, Tennessee. The company operates psychiatric hospitals, specialty treatment facilities and outpatient programs focused on mental health and substance use disorders.

Acadia's services include inpatient and outpatient psychiatric care, addiction treatment, residential treatment, eating-disorder programs, and services for children and adolescents. Its facilities serve patients with a range of behavioral health conditions, including depression, anxiety, trauma-related disorders and substance use disorders.

Founded in 2005, Acadia operates primarily in the United States and also has a significant presence in the United Kingdom through its ownership of Priory, a behavioral healthcare provider.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.